Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Sindall Group Regulatory News (MGNS)

Share Price Information for Morgan Sindall Group (MGNS)

Share Price is delayed by 15 minutes
Get Live Data
4,948.00    4.00 (0.08%)
Bid:
4,956.00
Ask:
4,964.00
Spread: 8.00 (0.161%)
Market Cap: £2.31b
MGNS Live PriceLast checked at - London Stock Exchange

Intraday Morgan Sindall Group Share Chart

AGM Voting Update

4 Sep 2023 12:51

RNS Number : 3096L
Morgan Sindall Group PLC
04 September 2023
 

Morgan Sindall Group plc

Legal Entity Identifier (LEI) number: 2138008339ULDGZRB345

 

4 September 2023

Morgan Sindall Group plc ("the Company")

 

Update on response to 2023 AGM voting outcome

 

At our Annual General Meeting ('AGM') held on 4 May 2023, resolution 3 (Approval of the Directors' Remuneration Policy) was supported by a large majority of shareholders but received less than 80% support overall.

 

In advance of the 2023 AGM, the Remuneration Committee (the 'Committee') undertook a detailed engagement with the Company's largest shareholders in relation to the remuneration proposals, and had amended the final Remuneration Policy design in response to feedback received. Following the 2023 AGM, the Committee reached out to the Company's largest shareholders to continue the dialogue and listen to their views - and in particular to understand why those who either abstained or voted against the Directors' Remuneration Policy ('the 'Policy') had done so.

 

The Committee received responses from eight investors, the majority of whom reconfirmed support for the Policy and the management team. 

 

One shareholder raised the annual bonus deferral requirement and 2nd-year phasing down of the post-employment shareholding requirement as their reason for not supporting the resolution. In both cases the Committee is comfortable that its current approach supports appropriate alignment of executive and shareholder interests. In respect of the annual bonus deferral requirement, the Committee also considers this requirement appropriate given the current shareholdings of incumbent Executive Directors. However, the Committee will reconsider both of these Policy design features as part of the next Policy review.

 

The Committee also received feedback from two shareholders that their voting had reflected the 'against' recommendation from one of the major proxy voting agencies, which itself was primarily a result of the simultaneous increases to the Policy headroom available under the annual bonus and LTIP schemes. On this matter, the Committee maintains its view that the Policy should be sufficiently flexible to last for a full triennial review period rather than needing to revert to shareholders to seek incremental changes, and reiterates its commitment to write out to major shareholders in advance of using the increased maximum opportunities under either of the variable incentives.

 

Another shareholder requested that the Committee provide a full explanation in its Remuneration Report of the rationale for the adoption of any increase to the executive directors' incentive opportunities in future years, particularly in relation to the achievement of key strategic objectives, and this feedback is consistent with the current thinking of the Committee.

 

The Committee continues to be grateful for the feedback received and the two-way engagement with major shareholders. Given overall majority support was obtained for the Policy resolution, it is not proposed to make any further changes to the approach to remuneration that was set out in the 2022 Annual Report. The Company will, however, continue to keep the Policy under review over the coming years and welcomes ongoing dialogue with shareholders and proxy advisers.

 

 

Enquiries:

Clare Sheridan, Company Secretary +44 (0) 20 7307 9200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFZLFBXKLEBBF
Date   Source Headline
17th Jun 20257:00 amRNSTrading Update and Outlook for 2025
16th Jun 20251:55 pmRNSDirector/PDMR Shareholding
2nd Jun 20253:45 pmRNSTotal Voting Rights
2nd Jun 202511:14 amRNSCompany Secretary Change
8th May 20258:36 amRNSAdditional Listing
7th May 20252:30 pmRNSHolding(s) in Company
1st May 202512:42 pmRNSResult of AGM
1st May 20259:30 amRNSTotal Voting Rights
1st May 20257:00 amRNSTrading Update
22nd Apr 20252:00 pmRNSCompany Secretary Change
22nd Apr 202510:11 amRNSBlock listing Interim Review
22nd Apr 20258:43 amRNSHolding(s) in Company
1st Apr 20259:38 amRNSTotal Voting Rights
27th Mar 20259:53 amRNSDirector/PDMR Shareholding
25th Mar 20251:50 pmRNSAdditional Listing
25th Mar 20257:00 amRNSTrading Update
24th Mar 20254:32 pmRNSHolding(s) in Company
20th Mar 20252:08 pmRNSAnnual Financial Report
14th Mar 202511:14 amRNSDirector/PDMR Shareholding
7th Mar 20251:33 pmRNSDirector/PDMR Shareholding
7th Mar 20251:26 pmRNSDirector/PDMR Shareholding
6th Mar 20254:42 pmRNSDirector/PDMR Shareholding
6th Mar 20254:38 pmRNSDirector/PDMR Shareholding
5th Mar 20258:56 amRNSDirector/PDMR Shareholding
3rd Mar 20259:41 amRNSTotal Voting Rights
26th Feb 20257:00 amRNSResults for the Full Year Ended 31 December 2024
19th Feb 20253:20 pmRNSHolding(s) in Company
11th Feb 202512:00 pmRNSAppointment of Joint Corporate Broker
7th Feb 20252:37 pmRNSHolding(s) in Company
3rd Feb 202510:10 amRNSTotal Voting Rights
16th Jan 20257:07 amRNSDirector Declaration
16th Jan 20257:00 amRNSNotice of Full Year Results
15th Jan 20257:00 amRNSDirectorate Change
2nd Jan 202511:56 amRNSTotal Voting Rights
20th Dec 20243:54 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:02 amRNSTotal Voting Rights
6th Nov 20241:18 pmRNSHolding(s) in Company
1st Nov 202410:33 amRNSTotal Voting Rights
30th Oct 20244:17 pmRNSDirector/PDMR Shareholding
28th Oct 20249:24 amRNSDirector/PDMR Shareholding
22nd Oct 20247:00 amRNSTrading Update and Outlook for 2024
21st Oct 20249:27 amRNSBlock listing Interim Review
15th Oct 202412:22 pmRNSAdditional Listing
1st Oct 202412:09 pmRNSTotal Voting Rights
27th Sep 20242:46 pmRNSDirector/PDMR Shareholding
10th Sep 202411:44 amRNSAdditional Listing
2nd Sep 202410:45 amRNSTotal Voting Rights
30th Aug 202410:35 amRNSHolding(s) in Company
30th Aug 20249:29 amRNSDirector/PDMR Shareholding
23rd Aug 20242:48 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.